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Proteinuria and hypertensive nephrosclerosis in African Amer-
icans. Proteinuria is a known risk factor for both renal dis-
ease progression and cardiovascular morbidity and mortality
in hypertensive populations. African Americans are among the
highest risk groups for development of renal disease in the set-
ting of hypertension and suffer a disproportionate burden of
end-stage renal disease attributed to hypertension. Population-
based studies indicate that African Americans have higher rates
of albuminuria compared to non-African Americans in part due
to higher rates of hypertension and diabetes in African Amer-
icans as compared to non-Hispanic whites for example. The
African American Study of Kidney Disease and Hypertension
(AASK) Trial was a prospective long-term clinical trial that ex-
amined the effect of aggressive blood pressure lowering versus
usual blood pressure lowering in three different classes of anti-
hypertensives on renal outcomes in approximately 1200 African
Americans with hypertensive nephrosclerosis. Two thirds of
trial participants had <300 mg protein, and one third had ≥300
mg of protein in a 24-hour urine specimen at baseline. Those
with >300 mg protein excretion compared to those with <300
mg protein excretion at baseline had more rapid decline in renal
function and ESRD events. Moreover, lower levels of protein-
uria than previously thought may be important for identifying
those at higher risk for kidney disease progression. The AASK
cohort study, a follow-up to the trial, is now underway. The
longer term follow-up will provide new insights into protein-
uria and other risk factors for progression of kidney disease in
hypertensive nephrosclerosis.
Albuminuria is a relatively common finding among
African Americans. Data from the NHANES III survey
indicate that about 8% of African Americans have an
abnormal rate of albumin excretion. Moreover, this is
nearly 50% higher than prevalence among non-African
Americans [1]. Also significantly higher urine albumin ex-
cretion rates are observed in African Americans in those
over age 40 compared with Hispanics and non-Hispanic
whites in this age range. This increased prevalence is due
in large part to the higher rates of hypertension and dia-
betes mellitus among this ethnic group [1, 2]. In addition,
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the lower rates of blood pressure control among hyper-
tensive African Americans may also contribute to higher
prevalence of albuminuria because higher blood pressure
can be associated with excessive albumin excretion rate
[2–4]. Another factor that may contribute to albuminuria
prevalence among African Americans is the higher inci-
dence of focal segmental glomerulosclerosis in this popu-
lation [5–8]. Albuminuria is a hallmark of FSGS, and may
be a harbinger of this relatively common form of human
glomerulopathy.
As in other populations, albuminuria is associated with
diabetes and hypertension among African Americans,
and cardiovascular morbidity and mortality are higher
in African Americans compared to Caucasians [1–3]. Hy-
pertensive African Americans with albuminuria are more
likely to develop heart failure [9], and African Americans
in the ARIC study are more likely to develop cardiovas-
cular complications in the presence of albuminuria.
End-stage renal disease (ESRD) attributed to hyper-
tension occurs at a rate that is five-fold higher among
African Americans compared to non-African Americans
[10]. The reasons for this discrepancy remain unclear.
Therefore, efforts to identify and treat hypertension and
proteinuria among this population are an important pub-
lic health issue. Recent analyses from the NHANES III
database and USRDS suggest that the higher incidence
of ESRD in African Americans is related to increased
rate of progression of chronic kidney disease (CKD), and
not increased prevalence. Moreover, two major factors
associated with more rapid progression of CKD among
African Americans are hypertension and albuminuria
[4].
METHODS
The African American Study of Kidney Disease and
Hypertension was a multicenter prospective, random-
ized, controlled trial involving nearly 1100 nondiabetic
adult African Americans with longstanding hypertension
and reduced glomerular filtration rate. Participants in this
trial were deemed to have hypertensive nephrosclerosis
as the underlying cause for CKD based on clinical and
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Fig. 1. Distribution of baseline urine protein creatinine ratio for par-
ticipants in the African American Study of Hypertension and Kidney
Disease (AASK) trial.
biochemical characteristics. The study was a 2 × 3 fac-
torial design in which participants were assigned to one
of two levels of blood pressure control (lower BP group,
mean arterial pressure <92 mm Hg and usual BP group
mean arterial pressure 102–107 mm Hg), and one of three
different antihypertensive-based regimens administered
once daily [10]. These classes included the beta-blocker
metoprolol, the dihydropyridine calcium channel blocker
amlodipine, and the angiotensin II–converting enzyme
inhibitor ramipril. Participants were followed-up to four
years with measurements of glomerular filtration rate and
urine protein at baseline, and every six months during
follow-up. The primary outcome was the rate of decline in
glomerular filtration rate estimated by renal clearance of
iothalamate. The main secondary outcome was a compos-
ite of rapidly declining GFR (50% reduction or >25 mL/
min/1.73m2 from baseline), ESRD, or death from any
cause. An additional secondary outcome was the change
in urine protein excretion rate from baseline. Urinary
protein excretion rate and creatinine clearance were mea-
sured by 24-hour urine collection conducted at baseline,
and repeated at six-month intervals during the trial. There
was no difference in the primary or secondary outcome
for blood pressure groups, or in the rate of decline in GFR
among antihypertensive classes. However, those assigned
to ramipril had a significantly lower rate of composite out-
come and ESRD alone.
RESULTS AND DISCUSSION
As illustrated in Figure 1, approximately two thirds of
study participants had a urine protein/creatinine ratio of
≤0.22 g/g, and one third had a ratio >0.22 g/g. Analysis
of change in urine protein excretion rate indicated that
urine protein increased over time, regardless of group as-
signment. However, the increase in urine protein excre-
tion was greater in those assigned to the usual compared
to the lower BP group and those assigned to amlodip-
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Fig. 2. Association of baseline urine protein creatinine ratio and GFR
slope by blood pressure group (A) and % events (rapidly declining
GFR or ESRD or death) (B). The rate of decline is illustrated for those
assigned to usual (U) and lower (L) blood pressure groups by quartile
of baseline urine protein creatinine ratio.
ine compared to ramipril or metoprolol. Further analysis
of the relationship of proteinuria to outcomes was inves-
tigated. Among AASK participants, those with higher
urine protein/creatinine ratios at baseline had faster rate
of decline in GFR and higher incidence of the composite
end point (Fig. 2) regardless of BP group. It is important
to note that MAP was maintained approximately 10 mm
Hg lower in the lower BP group compared to the usual
BP group. There were no differences in rate of decline in
GFR among drug treatment groups for those with base-
line urine protein excretion ≤0.22 g/g. In sharp contrast,
those with urine protein creatinine ratio >0.22 assigned
to amlodipine had a rate of decline in GFR approximately
two-fold faster than those assigned to ramipril, and about
1.2 times faster than those assigned to metoprolol (Fig. 3).
The rate of decline in glomerular filtration rate was sim-
ilar among different classes of antihypertensive agents
for any level of baseline urine protein excretion, except
for those participants with urine protein creatinine ex-
cretion rate >0.66 g/g assigned to amlodipine. Among
participants with a baseline urine protein creatinine ra-
tio >0.66 g/g assigned to amlodipine, the rate of de-
cline in GFR was doubled compared to those assigned to
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Fig. 3. Relationship between the rate of decline in GFR by drug treat-
ment assignment for those with a baseline urine protein creatinine ra-
tio > 0.22. The rate of decline was more rapid in those assigned to
amlodipine.
ramipril. In addition, higher urine protein excretion rate
was associated with a three-fold higher event rate for the
composite outcome (Fig. 2B). Interestingly, the rate of
rise in urine protein excretion among those assigned to
amlodipine was attenuated by lower blood pressure as-
signment, but this did not translate into a slower rate of
decline in GFR for the amlodipine compared to the other
groups.
To assess whether the urine protein excretion was an
independent predictor of ESRD, multivariate analysis
was performed controlling for baseline GFR level. In this
analysis, the level of baseline urine protein was an inde-
pendent predictor of subsequent development of ESRD,
even among those with the lowest levels of urine pro-
tein in the range of <0.08 g/g (unpublished observations).
Moreover, after controlling for randomized group, base-
line GFR, and change in GFR over the initial six months
of follow-up, the change in urine protein from baseline
to six-month follow-up was an independent predictor of
subsequent development of ESRD. The single measure-
ment of protein excretion rate at six months was also
shown to predict the subsequent development of ESRD.
And, after controlling for baseline proteinuria, baseline
GFR did not predict the rate of decline in GFR. Taken to-
gether, these findings suggest that urine protein excretion
in African Americans with hypertensive nephrosclerosis
is an independent predictor of subsequent decline in kid-
ney function. For the clinician, these analyses from the
AASK trial strongly suggest that both lowering blood
pressure and protein excretion rate are important for
slowing the rate of decline in kidney function and re-
ducing the risk of ESRD.
Future studies are needed to further evaluate the re-
lationship of proteinuria and its reduction with specific
interventions on outcomes in patients with hypertensive
nephrosclerosis. The African American Study of Kidney
Disease and Hypertension cohort study [14] is a follow-
up of participants in the AASK Trial. In the cohort study,
albuminuria along additional clinical, biochemical, en-
vironmental, and genetic factors will be examined as
potential kidney disease progression promoters (AASK
cohort). An important question is whether strategies
specifically designed to target lowering proteinuria are
renoprotective in hypertensive nephrosclerosis. Clinical
trials focusing on lowering proteinuria in this population
are needed to address this important question.
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